The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
“The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market, byend user, during the forecast period”
The pharmaceutical contract development and manufacturing market is segmented intobig pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users.The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2020. This segment’s high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.
“Biologics manufacturing services segment accounted for the highest CAGR”
Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing servicessegment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.
“Asia Pacific: The fastest-growing countryin thepharmaceutical contract development and manufacturing market”
Thepharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80%and Demand Side 20%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
This report provides a detailed picture of thepharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.